Duke Has Quietly Discontinued a Costly, Unproven Autism Treatment
By Anna Merlan,
| 04. 17. 2023
For several years, parents of autistic children have paid between $10,000 and $15,000 to have their children undergo unproven stem cell and cord blood treatments at Duke University, through what’s called an expanded access program, or EAP. That practice has attracted criticism from observers and ethicists in the stem cell field, who have asked why Duke was charging money for a service when its own clinical trials have not been very promising. In recent months, Duke has sent letters informing parents that this program is no longer available to autistic children—raising new questions about what those parents, who’d been led to believe the treatment might be a panacea for their kids, will do instead.
One of the more urgent questions is whether parents who can’t access the treatment though Duke will instead go to a for-profit partner with ties to the school. That would be Cryo-Cell International, which previously announced that it had entered into a licensing agreement with Duke allowing it to offer the same stem cell infusions in private, for-profit clinics the company has said it plans to... see more
"Human Egg" by euthman is licensed under CC BY 2.0.
In late April, the National Academies held a three-day workshop on In Vitro Derived Human Gametes as a Reproductive Technology
. Experts from a broad range of fields commented on the fast-developing science, its potential applications in assisted reproduction, and its social implications. Despite a focus on the significant technical challenges that remain in developing these techniques and the notable inclusion of several critical voices, the overall...
By Carolyn Y. Johnson, The Washington Post | 04.28.2023
DACULA, Ga. — For as long as he can remember, Jimi Olaghere felt he was destined to be a father. “It’s so true in my soul,” he told his wife, Amanda, when they struggled to get pregnant. But when they...
By David Jensen, The California Stem Cell Report | 04.24.2023
What good is a “miraculous” cure or a revolutionary therapy -- which is the goal of a $12 billion state of California enterprise -- if it is not accessible to patients?
That’s a question implicitly posed by a former member...
By Françoise Baylis, The Conversation | 04.12.2023
In January 2017, I met Jiankui He, the now-infamous Chinese scientist who would go on to create the world’s first genome-edited babies. This was at a meeting in Berkeley, Calif., hosted by Jennifer Doudna who, along with Emmanuelle Charpentier...